ProCE Banner Activity

Real-world Experiences With Long-Acting Injectable ART From IDWeek and EACS 2023

Conference Coverage
Clinical Thought

Do the experiences of people living with HIV who are receiving injectable CAB + RPV reflect the results reported in clinical trials? What can we learn about real-world rates of virologic failure and virologic resistance from the data presented during IDWeek and EACS 2023?

Released: November 09, 2023

Share

Faculty

Don E Smith

Don E Smith, MD, FRCP (London) FAChSHM

Senior Staff Specialist
Conjoint Professor
School of Clinical Medicine
University of New South Wales
Albion Centre
Sydney, Australia

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc., Janssen Therapeutics, Division of Janssen Products, LP, Merck & Co., Inc., Rahway, NJ, USA and ViiV Healthcare.

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Disclosure

Primary Author

Don E Smith, MD, FRCP (London) FAChSHM

Senior Staff Specialist
Conjoint Professor
School of Clinical Medicine
University of New South Wales
Albion Centre
Sydney, Australia

Don Smith, MD: consultant/advisor/speaker: Gilead Sciences, ViiV Healthcare; researcher: GlaxoSmithKline.